IRON news, real time IRON stock news, Disc Medicine Inc news today

News

IRON

80.04

-11.50%

-10.40

Jefferies sees ‘overreaction’ to article on Disc Medicine’s EPP approvability

TipRanks · 6h ago

Disc Medicine (IRON): Constructive FDA Dialogue and APOLLO Progress Support Buy Rating Despite Volatility

TipRanks · 6h ago

BMO Capital says call with Disc management clarifies active FDA dialogue

TipRanks · 6h ago

TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact

TipRanks · 7h ago

BUZZ-Disc Medicine drops on report of FDA skepticism over rare blood disorder drug

Reuters · 7h ago

Disc Medicine Enters Oversold Territory (IRON)

NASDAQ · 8h ago

Disc Medicine falls -14.3%

TipRanks · 9h ago

FDA voucher program allowing White House to intervene, STAT reports

TipRanks · 9h ago

Disc Medicine Insider Transaction Raises Eyebrows on Wall Street

TipRanks · 1d ago

Director Kevin Bitterman Reports Disposal of Disc Medicine Inc. i Common Shares

Reuters · 1d ago

Disc Medicine Director Kevin Bitterman Reports Disposal of Common Shares

Reuters · 2d ago

Disc Medicine Chief Medical Officer William Jacob Savage Sells Common Shares

Reuters · 2d ago

Disc Medicine Price Target Raised to $109.00/Share From $91.00 by Wells Fargo

Dow Jones · 3d ago

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones · 3d ago

Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $109

Benzinga · 3d ago

Analysts Offer Insights on Healthcare Companies: SI-Bone (SIBN), Disc Medicine (IRON) and Novan (NOVN)

TipRanks · 3d ago

DISC MEDICINE, INC. <IRON.O>: WELLS FARGO RAISES TARGET PRICE TO $109 FROM $91

Reuters · 3d ago

Disc Medicine CEO John D. Quisel Reports Sale of Common Shares

Reuters · 4d ago

Weekly Report: what happened at IRON last week (1208-1212)?

Weekly Report · 4d ago

EXCLUSIVE-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict

Reuters · 12/12 11:00

Webull provides a variety of real-time IRON stock news. You can receive the latest news about Disc Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.

About IRON

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.